Logo
x

Search

Subscribe Now

Mustang Bio

Mustang Bio Reports the US FDA’s Acceptance of IND Application for MB-109 to Treat Recurrent Glioblastoma and High-Grade Astrocytoma

Mustang Bio Reports the US FDA’s Acceptance of IND Application for MB-109 to Treat Recurrent Glioblastoma and High-Grade Astrocyto...

  • October 27, 2023
Mustang Bio Presents Updated P-I/II Trial Results of MB-106 for the Treatment of Waldenstrom Macroglobulinemia at EHA 2023

Mustang Bio Presents Updated P-I/II Trial Results of MB-106 for the Treatment of Waldenstrom Macroglobulinemia at EHA 2023

  • June 13, 2023
PharmaShots Weekly Snapshots (October 24 - 28, 2022)

PharmaShots Weekly Snapshots (October 24 - 28, 2022)

  • October 28, 2022
Mustang Bio Presented P-I/II Clinical Trial of MB-106 for Waldenstrom's Macroglobulinemia at 11th International Workshop

Mustang Bio Presented P-I/II Clinical Trial of MB-106 for Waldenstrom's Macroglobulinemia at 11th International Workshop

  • October 28, 2022
PharmaShots Weekly Snapshots (May 16 - 20, 2022)

PharmaShots Weekly Snapshots (May 16 - 20, 2022)

  • May 20, 2022
Mustang Bio Provides Updates of MB-107 in the P-I/II study for the Treatment of X-Linked Severe Combined Immunodeficiency

Mustang Bio Provides Updates of MB-107 in the P-I/II study for the Treatment of X-Linked Severe Combined Immunodeficiency

  • May 20, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.